Licensed vaccine
M-M-R II
FDA-licensed vaccine · Merck Sharp & Dohme LLC · STN BL 101069
Key facts
| Trade name | M-M-R II |
|---|---|
| Proper name | Measles, Mumps, and Rubella Virus Vaccine, Live |
| Manufacturer | Merck Sharp & Dohme LLC |
| Submission tracking number (STN) | BL 101069 |
| FDA product areas | Biologics, Vaccines |
| Recent FDA documents | November 5, 2024 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live, August 21, 2023 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live, Statistical Review - Measles, Mumps, and Rubella Virus Vaccine Live, February 27, 2023 Clinical Review Memo - Measles, Mumps, and Rubella Virus Vaccine Live, February 27, 2023 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live, December 11, 2020 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live, June 19, 2020 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live, May 16, 2017 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live, Patient Package Insert - Measles, Mumps, and Rubella Virus Vaccine Live, Package Insert - Measles, Mumps, and Rubella Virus Vaccine Live, Supporting Documents older than three years - MMR II |
| FDA page updated | Nov 6, 2024 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 1–9 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: